secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263534
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA
----------------------------------------------------------------------------

- First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.
- Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.
- Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.
- Topline results from primary and secondary endpoints are anticipated in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/0001193125-25-263534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer